GYRE (Gyre Therapeutics Inc) Earnings per share for the last twelve months

Public company logo of Gyre Therapeutics Corp. (GYRE)

High barriers to entry due to anti-fibrosis patents drive the price action for Gyre Therapeutics, Inc. (GYRE). The time trajectory on the GURU.Markets chart for the annual EPS TTM growth rate has reached -456.10, reflecting the current level of the metric. Drug development relies on algorithms, while clinical trials are delegated to international CRO partners to minimize operational risks.

gyretx.com (GYRE): Earnings per share for the last twelve months from 11/23/2025 to 11/18/2026

Financial and market metric breakdowns for Gyre Therapeutics Inc (GYRE)

- market price and analyst price targets:
- business market valuation indicators:
Initial company analysis:Gyre Therapeutics GYRE
Signature product of Gyre Therapeutics

Efficiently delegating liver therapy clinical trials to external CROs minimizes operational risks for Gyre Therapeutics, Inc. (GYRE), directly impacting the bottom line. The TTM EPS dynamics measure the annual growth rate of net income per share, allowing investors to assess the actual efficiency of business scaling and the company's ability to outpace market inflation.